Statin Therapy

Although lipid-lowering medications are generally well tolerated, rare complications can include statin-associated autoimmune myopathy and drug-induced acute pancreatitis, a speaker reported.

In a cohort of more than 400,000 patients at high risk for CVD requiring primary prevention, less than half were taking appropriately dosed statins and less than 10% were taking nonstatin lipid-lowering therapies, researchers reported.

The National Lipid Association Scientific Sessions will be held today to Saturday and will spotlight statements on statin-associated muscle symptoms, sessions focusing on translational and implementation science and more.

Effects of alirocumab (Praluent, Sanofi/Regeneron) on coronary atherosclerosis in patients with acute MI undergoing PCI.

People with familial hypercholesterolemia and those on long-term, high-intensity statins had no greater risk for dementia than matched controls, per a study published in JAMA Network Open.

Duration of LDL-lowering therapy had a cumulatively beneficial effect on CV outcomes, according to a meta-analysis of 21 randomized clinical trials published in Circulation: Cardiovascular Quality and Outcomes.

Healio and Cardiology Today have compiled a list of the top read news in cardiology of March 2022.

WASHINGTON — In a new study, subcutaneous biweekly alirocumab, added to high-intensity statin therapy, resulted in greater coronary plaque regression in non-infarct-related arteries after 1 year in patients with acute MI.

Statin use was modestly associated with reductions in all-cause mortality, myocardial infarction and stroke, according to a recent systematic review and meta-analysis.

The link between statin-induced LDL lowering and reduction of CV outcomes may not be as robust as assumed, researchers who conducted a meta-analysis published in JAMA Internal Medicine concluded.